Advanced search
Publication Cover
Biomarkers Volume 23, 2018 - Issue 7
Submit an article Journal homepage
155
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction

Jennifer MiaoVanderbilt University Medical Center, Nashville, TN, USA; View further author information
,
Shi HuangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA; View further author information
,
Yan Ru SuDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; View further author information
,
Carrie A. LennemanDivision of Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; View further author information
,
Meera WrightSt. Thomas Health, Nashville, TN, USA; View further author information
,
Frank E. HarrellDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA; View further author information
,
Douglas B. SawyerMaine Medical Center, Center for Molecular Medicine, Scarborough, ME, USA; View further author information
&
Daniel J. LenihanCardiovascular Division, Washington University in St. Louis, St. Louis, MO, USACorrespondence[email protected]
View further author information
 show all
Pages 704-708 | Received 05 Feb 2018, Accepted 22 May 2018, Published online: 17 Aug 2018

References

  • Fang, S.J., et al., 2010. Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Chinese medical journal, 123 (24), 3597–3604.
  • Favreau-Lessard, A.J., Ryzhov, S., and Sawyer, D.B., 2016. Novel biological therapies targeting heart failure: myocardial rejuvenation. Heart failure clinics, 12 (3), 461–471.
  • Galindo, C.L., et al., 2015. Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failure. Journal of the American heart association, 4 (1), e000528.
  • Gao, R., et al., 2010. A phase II, randomized, double blind multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. Journal of the American college of cardiology, 55 (18), 1907–1914.
  • Geisberg, C.A., et al., 2011. Circulating Neuregulin 1β levels vary according to the angiographic severity of coronary artery disease and ischemia. Coronary artery disease, 22 (8), 577–582.
  • Hedhli, N., et al., 2011. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation, 123 (20), 2254–2262. May 24.
  • Jabbour, A., et al., 2011. Parenteral administration of recombinant human neuregulin-1 to patients with stable chornic heart failure produces favourable acute and chronic haemodynamic responses. European Journal of heart failure, 13 (1), 83–92.
  • Kuramochi, Y., Guo, X., and Sawyer, D.B., 2006. Neuregulin activates ErbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. Journal of molecular and cellular cardiology, 41 (2), 228–235.
  • Ky, B., et al., 2009. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation, 120 (4), 310–317.
  • Lemmens, K., Doggen, K., and De Keulenaer, G.W., 2007. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation, 116 (8), 954–960.
  • Lenihan, D.J., et al., 2016. A phase I, single ascending dose study of cimaglermin alfa (Neuregulin 1β3) in patients with systolic dysfunction and heart failure. JACC basic to translational science, 1 (7), 576–586.
  • Lenneman, C.G., 2014. Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure. Current heart failure reports, 11 (2), 134–138.
  • Liu, X., et al., 2006. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. Journal of the American college of cardiology, 48 (7), 1438–1447.
  • Parry, T.J., et al., 2017. Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequent on left ventricular function in rats following myocardial infarction. European journal of pharmacology, 796, 76–89.
  • Sawyer, D.B., et al., 2002. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: Potential mechanism for trastuzumab-induced cytotoxicity. Circulation, 105 (13), 1551–1554.
  • Xu, Y., et al., 2010. Neuregulin-1/ErbB signaling and chronic heart failure. Advances in pharmacology (san diego, calif.), 59, 31–51.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.